Dose Insider / Glossary / Gastroparesis

GastroparesisWhat it is and what GLP-1 medicines do to the stomach

Updated November 20, 2026 · 4 min read · NIDDK, ACG guideline 2022, FDA labels, JAMA 2023, Gastroenterology 2025

Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from the stomach to the small intestine.

9.1Claims study, per year, Semaglutide, gut problems per 1,000 people
Gut problems per 1,000 peopleClaims data and a review of 55 trialsCLAIMS STUDY, PER YEARSemaglutide9.1Liraglutide7.3Bupropion-naltrexone3.155 TRIALS, EXTRA CASESReflux disease4.0Gallstones2.0Gut problems per 1,000peopleClaims data and a review of 55 trialsCLAIMS STUDY, PER YEARSemaglutide9.1Liraglutide7.3Bupropion-naltrexone3.155 TRIALS, EXTRA CASESReflux disease4.0Gallstones2.0

For gastroparesis itself, the 55 trials found little or no effect.

On this page

The stomach muscles work poorly or not at all, and the stomach takes too long to empty.1 GLP-1 medicines slow stomach emptying as part of how they work, so the question of whether they cause gastroparesis comes up often. The evidence is split: one claims study found more diagnoses among users, while a pooled analysis of 55 trials found little or no effect on the risk.2,3

What it is

The American College of Gastroenterology adds two conditions in its 2022 guideline: there must be objective evidence of delayed emptying, and no mechanical blockage at the outlet of the stomach. Symptoms alone do not make the diagnosis.4 NIDDK lists the symptoms:1

The disorder is not common. NIDDK puts it at about 10 men and 40 women in every 100,000 people, while symptoms like those of gastroparesis occur in about 1 in 4 adults in the United States. Diabetes is the most common known cause, because it can damage the vagus nerve, which controls the stomach muscles.1

How GLP-1 medicines slow the stomach

All four labels of Ozempic, Wegovy, Zepbound and Mounjaro state that the drug delays gastric emptying; the Ozempic label calls the delay minor and counts it as part of how the drug lowers blood sugar after a meal.5,6,7,8 The size of the delay has been measured. A 2024 review pooled five studies with 247 participants that used a gastric emptying scan: the time for half a solid meal to leave the stomach was 138.4 minutes on a GLP-1 medicine and 95.0 minutes on placebo.9 For tirzepatide, the delay was largest after the first dose and shrank while people kept taking it.7,10

Do the medicines cause gastroparesis?

The claims study. A 2023 research letter in JAMA, based on insurance claims, recorded gastroparesis in 9.1 of every 1,000 semaglutide users a year, 7.3 among liraglutide users, and 3.1 of every 1,000 users of a comparison weight-loss drug, bupropion with naltrexone. The confidence interval was wide, 1.15 to 11.90, the result for semaglutide rested on four cases, and the data end in June 2020.2

The trials. A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants looked for gastroparesis among other gut events and concluded that GLP-1 medicines probably have little or no effect on its risk. The same analysis found more gallstones, 2 more cases per 1,000 people, and probably more reflux disease, 4 more per 1,000.3

NIDDK draws a useful line for other medicines that slow the stomach, such as opioid painkillers and pramlintide: they can cause symptoms like those of gastroparesis, but they do not cause gastroparesis itself. Its page predates the GLP-1 boom and does not mention these medicines.1

How it is diagnosed

Doctors diagnose gastroparesis from the medical history, an exam, the symptoms and tests that measure how fast the stomach empties, usually a 4-hour scan after a standard meal, once a blockage has been ruled out.1 NIDDK asks patients to tell the doctor about every medicine they take. Whether to pause a GLP-1 medicine before a test is for the doctor ordering it; none of the sources here gives a rule.1

On the labels

All four labels say the medicine is not recommended for people with severe gastroparesis.5,6,7,8 They also warn about severe stomach and gut reactions and about aspiration during anesthesia, where a slow stomach has a recognized consequence. Our page on Ozempic and gastroparesis covers diagnosis, testing and what to do if symptoms persist.

Sources

  1. National Institute of Diabetes and Digestive and Kidney Diseases. Gastroparesis: Definition and Facts; Symptoms and Causes; Diagnosis; Treatment; Eating, Diet, and Nutrition. Last reviewed January 2018, read November 20, 2026. niddk.nih.gov
  2. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023;330:1795-1797. doi:10.1001/jama.2023.19574
  3. Chiang CH, Jaroenlapnopparat A, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
  4. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol 2022;117:1197-1220. doi:10.14309/ajg.0000000000001874
  5. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 12 and 17. accessdata.fda.gov
  6. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7 and 12. accessdata.fda.gov
  7. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
  8. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
  9. Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol 2024;119:1126-1140. doi:10.14309/ajg.0000000000002820
  10. Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886-1891. doi:10.1111/dom.14110

Related analyses

Log fullness, nausea and vomiting with your doses, and see whether they follow the shot.

Open Dose Insider